Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
1.670
+0.050 (3.09%)
At close: Dec 5, 2025, 4:00 PM EST
1.650
-0.020 (-1.20%)
After-hours: Dec 5, 2025, 7:06 PM EST
Ovid Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Ovid Therapeutics stock have an average target of 3.60, with a low estimate of 2.00 and a high estimate of 5.00. The average target predicts an increase of 115.57% from the current stock price of 1.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ovid Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $1.5 → $2 | Strong Buy | Maintains | $1.5 → $2 | +19.76% | Nov 24, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $5 | Buy | Initiates | $5 | +199.40% | Nov 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $1.5 | Strong Buy | Maintains | $2 → $1.5 | -10.18% | May 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +19.76% | Mar 24, 2025 |
| BTIG | BTIG | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +139.52% | Mar 24, 2025 |
Financial Forecast
Revenue This Year
6.67M
from 566.00K
Increased by 1,077.56%
Revenue Next Year
170.48K
from 6.67M
Decreased by -97.44%
EPS This Year
-0.50
from -0.37
EPS Next Year
-0.47
from -0.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 6.9M | 735,000 | ||||
| Avg | 6.7M | 170,483 | ||||
| Low | 6.4M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,126.3% | -89.0% | ||||
| Avg | 1,077.6% | -97.4% | ||||
| Low | 1,025.4% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.41 | -0.26 | ||||
| Avg | -0.50 | -0.47 | ||||
| Low | -0.59 | -0.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.